Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China.

Publication date: Dec 01, 2024

Vaccination has emerged as the primar approach for managing the COVID-19 pandemic. Despite certain clinical trials reporting the safety and immunogenicity of CoronaVac, additional multicenter real-world studies are still necessary. In this study, we recruited 506 healthy volunteers who were not infected with COVID-19 or vaccinated. Each participant provided peripheral blood samples three times: prior to the first dose of vaccine, prior to the second dose, and 8 weeks following the second dose. Ultimately, 388 participants completed the entire follow-up process. No serious adverse events were observed among any of the participants. Within 1 week of vaccination, 13. 4% of participants experienced systemic adverse reactions, with fatigue (5. 93%) and dizziness (3. 35%) being the most frequent. Although some clinical indicators, including creatinine, significantly changed after vaccination (p 

Concepts Keywords
8weeks CoronaVac
China immunogenicity
Pandemic neutralizing antibodies
Vaccinated prediction model


Type Source Name
disease VO CoronaVac
disease VO vaccination
disease MESH COVID-19 pandemic
disease VO vaccinated
disease IDO blood
disease VO dose
disease VO vaccine
disease IDO process
drug DRUGBANK Creatinine

Original Article

(Visited 1 times, 1 visits today)